SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, apparently newsless XCN price spike has put the token in focus, with traders debating whether the move can hold or is another pump-and-dump. Some are buying the pullback and pointing to improving Bitcoin momentum, while skeptics expect the gains to fade.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens IMDELLTRA-plus-Imfinzi combination showed a substantial survival benefit in a Phase 3 trial for first-line extensive-stage small-cell lung cancer, drawing attention to the drugs potential expansion and growth prospects. Traders are broadly positive on the result, while debating how much it could add to growth alongside established products such as Repatha.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee joined Irth Capitals effort to take the company private have revived takeover speculation and sparked bullish deal hopes. The transaction remains unconfirmed, and traders are divided between expecting a sale and doubting the board will agree, while weak sales, falling shares, and the dividend suspension fuel criticism of management.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL colorectal cancer results are driving discussion, with traders highlighting tumor responses and the possibility of organ preservation while questioning whether small, nonrandomized studies will translate into durable benefit. Optimism about the treatments potential is tempered by concerns over Phase 3 timing, dilution, and management execution.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on volatile Dow and broader-market moves amid rising Treasury yields, hawkish Fed concerns, and oil and geopolitical risks tied to Iran. Traders are divided between warnings of a deeper selloff and bullish calls for a rebound, with some noting the Dows relative strength versus tech-heavy indexes.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is drawing attention amid volatile crude prices and Middle East supply risks, particularly uncertainty around Iran and Strait of Hormuz disruptions. Traders debate whether geopolitical tensions and tight supply will support oil producers or whether ceasefire headlines, inventory builds, and a possible return of supply will pressure shares; some also point to PRs operating results and higher production guidance.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

A beat-and-raise quarterly report and a third increase to MaxLinears 2026 optical data-center outlook are reinforcing its AI optics growth story. Traders are divided as the shares fall despite the strong update, citing higher expectations, cash-flow concerns, and competition in high-speed interconnects.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMCs sharp outlook reset, driven by price cuts on distributor-held inventory and weak demand, is fueling concern about its business outlook and debt burden. Traders are split between fears of further financial distress and the view that the inventory reset and debt-reduction efforts could support a longer-term turnaround.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

OXLC is drawing attention amid a steep share-price decline and concern that upcoming results may show weaker core income and further NAV deterioration, based on traders reading of a recent filing. The discussion is split between claims of a short attack and bearish concerns about credit-market exposure, NAV erosion, and whether the high distribution can be sustained.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds quarterly results and weaker-than-expected profit outlook have focused attention on rising jet-fuel costs and pressure on margins, despite strong revenue and travel demand. Traders are split between concern over the guidance and optimism that resilient bookings and a recent share-price rebound may offset the bad news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback 

Equity

The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus. 


Stellantis To Invest More Than €1B In France To Expand Van Production: Report 

According to a Bloomberg report, Stellantis is putting more than €1 billion into its Hordain van plant as part of a broader push to modernize its French manufacturing operations and strengthen its European commercial-vehicle business.


NVS Stock On Track For Worst Week In Over 7 Years After Two Trial Failures In A Week — Investor Reportedly Seeks Board Overhaul 

David Samra, managing director at Artisan Partners, told Reuters that Chairman Giovanni Caforio should tighten oversight of acquisitions, add an acquisitions committee, and recruit stronger board talent.


Want to Tap Global Growth? These Equity ETFs Could Benefit

Seeking growth beyond U.S. borders? Global equity ETFs could offer diversification and exposure to attractive opportunities across international markets.

Global ETFs to Diversify as Tech Weakness Weighs on Markets

The AI trade is under pressure as a semiconductor slump and financing concerns rattle markets, making global ETFs worth a closer look.

STLA Stock: Stellantis CEO Rules Out Maserati Sale But Hints At New Partnerships

Antonio Filosa revealed that Stellantis is currently negotiating with “two important partners” that could bring “technology, development and excellent ideas” to Maserati.


STLA Stock Pares Loses: Unveils €190 Billion 2030 Revenue Target 

Stellantis is looking to bring €190 billion in revenue from 2030, compared to €154 billion reported in 2025.


Global ETFs Back in the Spotlight on Macroeconomic Tailwinds

Easing geopolitical tensions, a softer dollar and improving risk appetite are reviving interest in global equity ETFs.

Global Equity ETFs in Focus as AI Optimism Drives Fresh Inflows

AI optimism and easing volatility fuel a $48.7B surge into global equity funds. Here are some global ETFs to consider.

Looking Abroad Again? Global ETFs to Diversify Beyond U.S. Markets

Ceasefire hopes, persistent volatility in the U.S. markets and a softer dollar are driving investors to look beyond domestic equities and toward global equity ETFs for broader diversification.

Dimensional ETF Trust - Dimensional International Core Equity Market ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy.</li><li>Novartis has faced multiple clinical setbacks over the past several weeks, including trial failures and development discontinuations.</li><li>According to data from Koyfin, 8 of the 23 analysts rate the stock a ‘buy’ or ‘strong buy,’ while 13 rate it a ‘hold’ and only two rate it ‘sell.’</li></ul> Shares of Novartis (NVS) closed little changed on Friday after the company decided to discontinue its mid-stage trial of iptacopan in lupus nephritis.According to a federal clinical trials registry update, the company has concluded the study over ‘strategic considerations.’ It is unclear if the discontinuation was spurred by efficacy or safety concerns.The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment. The company decided to conclude the study after completing the first part, as per the database.Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy.<h2 class="st-heading-2">Latest Pipeline Setback For Novartis</h2>Novartis has faced multiple clinical setbacks over the past several weeks. Last month, the company said that its late-stage trial of Pelacarsen, being developed as a treatment to lower elevated lipoprotein(a) or Lp(a) and reduce the risk of major cardiovascular events, missed its primary goal. The company also said that its late-stage trial of del-desiran in myotonic dystrophy type 1 (DM1) missed its primary endpoint.Besides the late-stage drug failures, the company also discontinued development of VHB937 in mid-September after a mid-stage study missed primary and secondary goals. &nbsp;Prior to that, in August, Novartis paused multiple autoimmune and neurology trials after three fatal cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) in patients taking its experimental therapy Rap-cel. &nbsp;According to data from Koyfin, 8 of the 23 analysts rate the stock a ‘buy’ or ‘strong buy,’ while 13 rate it a ‘hold’ and only two rate it ‘sell.’<h2 class="st-heading-2">How Did NVS Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NVS" data-symbol-id="NVS" href="https://stocktwits.com/symbol/NVS" target="_blank">NVS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.NVS stock has gained 9% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/asnd-shares-shrug-off-positive-european-opinion-for-fda-approved-achondroplasia-drug/cZxKWRBRBtT">ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus. 

Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback

Dimensional International Value ETF

Novartis AG

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

DFAI Dimensional ETF Trust - Dimensional International Core Equity Market ETF

Fundamentals

Latest DFAI News